ALFA Filings
Every announcement, straight from the exchange
Every Astec Lifesciences debt & borrowing announcement on NSE and BSE, newest first, each with its own page.
Time
14 announcements with these filters
Astec LifeSciences Limited has redeemed Commercial Papers amounting to ₹25 Crore. The payment was made on the maturity date, 13th October, 2026.
Astec LifeSciences fixed record dates for redemption of three CP series totaling Rs.75 Crore maturing Nov–Dec 2026. All three CPs are listed on the NSE debt segment.
Astec LifeSciences Limited has confirmed the timely payment of the maturity amount for its commercial paper. The redemption amount totals ₹25 Crore.
Astec LifeSciences has set record dates for the redemption of three Commercial Paper series, with each series maturing at a value of ₹25 Crore.
Astec LifeSciences Limited successfully redeemed its listed Commercial Paper worth ₹25 Crore on maturity. The timely payment reinforces the company's financial discipline and debt servicing reliability.
Astec LifeSciences Limited confirmed the timely redemption of ₹25 Crore worth of Commercial Papers. The payment was made upon maturity on May 22, 2026.
Astec LifeSciences fixed June 2026 record dates for redeeming four Commercial Paper series. Investors should track these dates to ensure timely receipt of maturity payments.
Astec LifeSciences Limited confirmed the timely redemption and payment of ₹25 Crore for its Commercial Papers (Series ASTEC-CP-186). The papers matured on April 29, 2026. This announcement demonstrates the company's adherence to its debt obligations and financial stability.
Astec LifeSciences Limited has fixed the record dates for the redemption of two Commercial Paper series maturing in May 2026. The total redemption amount is ₹50 Crore, split across two ₹25 Crore tranches listed on the NSE.
Astec LifeSciences Limited issued a compliance certificate for its 8.90% Unsecured Non-Convertible Debentures totalling ₹49 Crore. As the NCDs are unsecured, the company filed a nil security cover certificate for the quarter ended March 31, 2026.
Astec LifeSciences Limited submitted its annual disclosure for the centralized database of corporate bonds as of March 31, 2026. The filing confirms listing details and interest payment status for its ₹49 Crore Non-Convertible Debentures (ISIN: INE563J08023). ICRA reaffirmed the credit rating at [ICRA]AA- with a negative outlook.
Astec LifeSciences Limited successfully redeemed its Commercial Paper (Series Astec-CP-188) by making a timely payment of ₹25 Crore on April 15, 2026. The instrument, originally issued in November 2025, was listed on the NSE.
Astec LifeSciences Limited certified that it did not issue any fresh Commercial Paper (CP) during the quarter ended March 31, 2026. This filing is a regulatory compliance confirmation regarding the utilization and status of issue proceeds under SEBI regulations.
Astec LifeSciences Limited reported the status of its private placement debt securities for the half-year ended March 31, 2026. The company has ₹49 Crore outstanding in 8.90% Non-Convertible Debentures (ISIN: INE563J08023) maturing in March 2027. This filing is a routine regulatory disclosure under SEBI's master circular for debt securities.